Apellis Pharmaceuticals first received approval for its drug pegcetacoplan in the treatment of paroxysmal nocturnal hemoglobinuria in 2021 - projected revenues in this indication in 2023 are $91m.The ...
Source LinkApellis Pharmaceuticals first received approval for its drug pegcetacoplan in the treatment of paroxysmal nocturnal hemoglobinuria in 2021 - projected revenues in this indication in 2023 are $91m.The ...
Source Link
Comments